Thyroid function suppression after initiation of teprotumumab treatment
Sign Up to like & getrecommendations! Published in 2021 at "Endocrine"
DOI: 10.1007/s12020-021-02676-3
Abstract: Teprotumumab, a monoclonal antibody that inhibits the insulin-like growth factor I receptor (IGF-IR), is newly approved for thyroid eye disease [1]. As IGF-IR forms a complex with the thyrotropin receptor (TSHR), mediating the actions of… read more here.
Keywords: thyroid function; initiation teprotumumab; teprotumumab treatment;
Teprotumumab Treatment for Thyroid-Associated Ophthalmopathy
Sign Up to like & getrecommendations! Published in 2020 at "European Thyroid Journal"
DOI: 10.1159/000507992
Abstract: Background: Thyroid-associated ophthalmopathy (TAO), an autoimmune process affecting the tissues surrounding the eye, most commonly develops in individuals with Graves’ disease. It is disfiguring, can cause vision loss, and dramatically lessens the quality of life… read more here.
Keywords: thyroid associated; treatment tao; treatment; teprotumumab treatment ... See more keywords
Role of teprotumumab in the treatment of active moderate-to-severe Graves' orbitopathy.
Sign Up to like & getrecommendations! Published in 2022 at "European thyroid journal"
DOI: 10.1530/etj-22-0185
Abstract: Graves' orbitopathy (GO), also named thyroid-associated orbitopathy (TAO) or thyroid-eye disease (TED), is an autoimmune inflammatory disease of the orbit and the most important extrathyroidal manifestation of Graves' disease. After an initial inflammatory ("active") phase… read more here.
Keywords: role teprotumumab; graves orbitopathy; treatment active; active moderate ... See more keywords